Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Temporal Dosing Tunes Glutathione Gradient across Liver-Blood-Tumor Axes to Boost the Chemotherapeutic Potency of Prodrug Nanoassemblies.

Created on 11 Nov 2026

Authors

Zuo Zhang, Baoyuan Zhang, Yongke Zhang, Siyun Zheng, Yiming Lu, Dongyu Zhang, Xinyu Cui, Jialin Xing, Jin Sun, Zhonggui He, Bingjun Sun, Yixin Sun

Published in

ACS nano. Volume 20. Issue 44. Pages 29747-29764. Nov 10, 2026.

Abstract

Redox-responsive prodrug nanodelivery systems hold immense promise in cancer therapy, offering advantages of improved pharmacokinetics, enhanced tumor selectivity, and increased safety. However, compared with standard therapeutic formulations, prodrug nanodelivery systems fail to yield superior antitumor efficacy at equivalent doses, attributable to inadequate drug activation and intratumoral accumulation. Herein, the three-in-one drug-release module, comprising an α-disulfide bond, an ethylene glycol moiety, and a short carbon chain, was covalently linked to paclitaxel (PTX) to construct three prodrug nanoassemblies (PSBA10 NPs, PSBA12 NPs, PSBA14 NPs). Notably, PSBA10 NPs, which possessed the shortest carbon chain, exhibited hypersensitive redox-responsive drug release and potentiated antitumor efficacy. Although PSBA10 NPs exhibited better safety than paclitaxel solution (Taxol) at equivalent doses, superior efficacy remained unattainable. Interestingly, a temporal-dose-regulated glutathione (GSH) gradient across the liver-blood-tumor axis increased the intratumoral accumulation of PSBA10 NPs by approximately 3-fold, resulting in pronounced antitumor efficacy superior to Taxol. This transient depletion of GSH in the liver and blood reduced the cleavage of disulfide bonds in the systemic circulation, enhancing tumor accumulation and selective activation of PSBA10 NPs. Our study highlighted a tumor treatment model based on the synergistic strategy of structural optimization and GSH gradient regulation across the liver-blood-tumor axis to boost the efficacy of chemotherapy.

PMID:
43007778
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement